continues to to be made available via Cancer Drugs Fund after clinical trials . Trials , in 28 British hospitals , showed it to be extremely effective in treating mantle cell tumors and chronic lymphocytic disease . For now , ibrutinib ( which costs up to £ ##50 a week ) can be prescribed only to patients whose disease does n't respond to chemotherapy .
Ibrutinib to to be made available via Cancer Drugs Fund after two trials . Trials , in 28 British hospitals , showed it to be extremely effective in treating mantle cell lymphoma and chronic lymphocytic leukaemia . For now , ibrutinib ( which costs up to £74,000 a year ) will be prescribed only to patients whose disease does n't respond to chemotherapy .